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ABSTRACT
The patent literature is a rich catalog of biologically
relevant chemicals; many public and commercial
molecular databases contain the structures dis-
closed in patent claims. However, patents are an
equally rich source of metadata about bioactive
molecules, including mechanism of action, disease
class, homologous experimental series, structural
alternatives, or the synthetic pathways used to pro-
duce molecules of interest. Unfortunately, this
metadata is discarded when chemical structures
are deposited separately in databases. SCRIPDB is
a chemical structure database designed to make
this metadata accessible. SCRIPDB provides the
full original patent text, reactions and relation-
ships described within any individual patent, in
addition to the molecular files common to struc-
tural databases. We discuss how such information
is valuable in medical text mining, chemical image
analysis, reaction extraction and in silico pharma-
ceutical lead optimization. SCRIPDB may be
searched by exact chemical structure, substructure
or molecular similarity and the results may be re-
stricted to patents describing synthetic routes.
SCRIPDB is available at http://dcv.uhnres.utoronto
.ca/SCRIPDB.
INTRODUCTION
US patent information is in the public domain and de-
scribes innovations in the medical, biological, chemical
and agricultural ﬁelds. Such relevant and accessible
material is ideal for scientiﬁc analysis and, indeed, data-
bases such as PubChem (1) and ChEBI (2,3) contain
chemical structures disclosed by patents. While such
databases are highly useful, structural databases are insuf-
ﬁcient for a number of scientiﬁc investigations.
The extraction of component structures from a patent
discards information about chemical relationships. These
relationships can be explicitly labelled, such as a mol-
ecule’s role as reagent or product in a chemical synthesis.
Relationships may also be implicitly embedded in the
context of the complete patent. For example, molecules
that co-occur in drug patent claims are likely to have
similar biological behavior.
These exemplar relationships have been valuable in
statistical analyses for automated reaction extraction
(4,5) and bioisostere discovery (6). Reaction extraction
characterizes the molecular transformations that occur
within a set of syntheses. Bioisostere discovery catalogs
molecular substituents that participate in similar bio-
logical interactions. Such analyses require access to large
data sets, which are often unavailable, proprietary, or
expensive.
In addition to the relationships among a patent’s mo-
lecular structures, a patent’s data ﬁles are directly useful.
One use of patent ﬁles is the creation of data sets for
optical structure recognition. The task in optical structure
recognition is to parse a chemical image and recover the
depicted molecular structure. The training and tests sets
therefore require correctly matched pairs of images and
molecular structure ﬁles. As a ﬁnal example, a patent’s
written contents can serve as a target for text analytics.
Patent descriptions and claims constitute a large corpus of
biomedical text, coarsely annotated by, e.g., patent classi-
ﬁcation and drug–disease pairs.
To address these gaps in available metadata, we have
created SCRIPDB. While providing uncomplicated
searching of the patent literature, we have been careful
not to eliminate underlying information. Users of the
database may download the full text of the patent as
well as molecular structure ﬁles and images. Additional
summary ﬁles were generated and augment, rather than
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searchers to effectively access the full information con-
tained in the patent literature.
MATERIALS AND METHODS
Data collection and processing
The United States Patent and Trademark Ofﬁce (USPTO)
provides full patent text, drawings, and, since 2001,
chemical structures in complex work units. This data
became available as a free bulk download, hosted on
Google servers, in June 2010. The raw data ﬁles
comprise every granted patent, numbering several
thousand per week, and totaling over 10 terabytes of
data. However, most patents are not relevant to the bio-
logical, chemical or medical domains.
Since 2001, patented chemical structures can be
described using standard molecular ﬁle formats. The
USPTO makes disclosed molecules available as either
MDL Molﬁles (MOL) or ChemDraw binary CDX ﬁles.
We used the presence of these chemical structure ﬁles to
identify patents of potential interest. Figure 1 shows the
amount of data in SCRIPDB, as measured by the quantity
of CDX ﬁles (Figure 1a), individual structures (Figure 1a),
and patents (Figure 1b). These numbers are consistent
with previous analyses of patent data (7).
A particular structure will often be described with both
a CDX and Molﬁle. However, the information contained
in such parallel ﬁles is not always identical. For example, a
CDX ﬁle can label a molecule’s role in a reaction as
reagent or product, whereas a Molﬁle cannot. We
provide both CDX and Molﬁle data formats, as well as
original TIFF and generated SVG images. For additional
convenience, we collated the individual structure ﬁles into
one structure-data ﬁle (SDF) per patent. During collation,
the generated SDF ﬁles were ﬁltered to remove duplicate
molecules. The ﬁltering ensures that duplicated structures
are removed from individual patents’ SDF ﬁles but not
across patents, as shared molecules may be used to
uncover legitimate relationships among the patents.
Patents often describe sets of molecules rather than, or
in addition to, speciﬁc structures. Markush structure
notation is commonly used to succinctly describe large
(or inﬁnite) molecular classes by choosing constituent mo-
lecular fragments from alternatve substituents, positions,
frequencies or homologies. The enumeration and compari-
son of Markush classes are signiﬁcant challenges for
cheminformatics systems (8). For example, Markush
structures typically depict variable substituent placement
as bonds that cross rings, as in Figure 2. These bonds
frequently appear in Molﬁles as separate propane mol-
ecules laid over the core scaffold. SCRIPDB provides
basic Markush handling by extracting the molecular
core and canonicalizing variable substituents, which per-
mits Markush structures to be found via substruc-
ture searches. The original Markush structure is then
retrievable from the original patent’s structure or image
ﬁles.
Figure 1. Cumulative SCRIPDB content. Although SCRIPDB includes patents from 2011, we show data through 2010, the last complete year.
(a) shows the number of ChemDraw CDX structure ﬁles, and the structures described therein, available in SCRIPDB for various years. SCRIPDB
contains 4 814 913 CDX ﬁles from 2001 through 2010, comprising 10840646 molecules. Duplicate molecules were ﬁltered from each patent but not
across patents, as described in the text. (b) shows the number of patents and details the subset containing reactions. For 2001 through 2010,
SCRIPDB contains 107560 patents, of which 25048 contain synthetic reactions.
Figure 2. Example Markush structure from US Patent 6268504 (9)
deﬁning a chemical class via substituent, positional and frequency
variations.
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Raw patent data was downloaded from Google’s bulk
download of USPTO granted patents with embedded
image data (http://www.google.com/googlebooks/
uspto-patents-redbook.html). Filtering, collation and
de-duplication were performed on an IBM CL1350
cluster with 1344 cores over 168 Inﬁniband-connected
HS21-XM BladeServers and a DCS9550 storage system.
The cluster runs the CentOS operating system, version 5.1,
and manages coarse-grained parallelism with the Portable
Batch System. SDF ﬁles were generated and duplicate
structures were removed using OpenBabel, SVN revision
4487 (10). OpenBabel was also used to generate SVG ﬁles
and compute canonical SMILES strings (http://www
.daylight.com/smiles/) for display of retrieved search
results, as shown in Figure 3.
The web interface to SCRIPDB was implemented in
Python 2.6 using the Django web application frame-
work, version 1.1 (11). Chemistry-speciﬁc search func-
tionality, such as substructure searches or structural
similarity using the Tanimoto coefﬁcient (12)o f
OpenBabel FP2 linear structural ﬁngerprints, is provided
via integration with Pybel (13). Search structures may be
speciﬁed via SMARTS queries, uploaded Molﬁles, or via
the interactive ChemWriter molecular editor (http://
metamolecular.com/chemwriter/). ChemWriter is imple-
mented in pure Javascript and permits SCRIPDB to be
accessed from any major browser for desktop or iPad
without the installation of external plugins.
RESULTS
Structures
New patents are granted each week, providing a steady
stream of additional data for SCRIPDB. Here, we report
results to the end of 2010, which is the last complete year
of patent data. At the end of 2010, SCRIPDB contained
107 560 patents, including 4814913 non-redundant CDX
structure ﬁles. Many structure ﬁles describe multiple mol-
ecules which, after de-duplication of molecules within a
patent, yield a total of 10 840 646 molecules. Not only
does this constitute a signiﬁcant amount of total data (7)
but the rate of structure disclosure appears to be growing.
Both 2009 and 2010 had record numbers of molecules
disclosed, at 1259097 and 1639522 structures, respective-
ly. SCRIPDB data statistics are summarized in Figure 1.
However, focusing solely on the chemical structures
ignores valuable chemical information. For many applica-
tions, molecular relationships need to be analyzed at
various levels of granularity; for example, within a single
CDX ﬁle, a particular patent, a group of patents that refer
to a speciﬁc disease, or within the entirety of the database.
As seen in Figure 1, patents typically contain multiple
structural ﬁles which, in turn, contain multiple structures.
For example, US Patent 6 884 815 contains 8 187 structure
ﬁles (14).
Figure 4 shows the distribution of molecules per patent.
The largest group contains patents that describe relatively
few molecules (speciﬁcally, 10 or fewer). However, most
patents catalog larger structural series. Two-thirds
Figure 3. Sample of search results for molecules containing an acridine substructure.
D430 Nucleic AcidsResearch, 2012, Vol.40,Database issueof patents contain more than 10 structures, over half of
patents contain more than 20 structures, and almost 1 300
patents describe more than 1000 structures each. A
manual examination of a sample of patents shows that
these structures often describe molecular analogs
produced in the context of a medicinal chemistry opti-
mization program.
Synthetic reactions
An important relationship described in CDX ﬁles is
chemical synthesis. Figure 1b details the subset of
patents that contain reactions. These are the patents
that contain a CDX ﬁle with a ReactionStep object
(http://www.cambridgesoft.com/services/documentation/
sdk/chemdraw/cdx/ReactionStep.htm). Of the 107560
patents from 2001 to 2010, SCRIPDB contains 25 048
patents that describe syntheses.
Fundamental molecular roles, such as reagent and
product, are lost when a synthesis is split into separate
structures. These relationships may be difﬁcult to
rederive, especially in multistep syntheses. Figure 5,
which shows the number of reaction steps in
SCRIPDB’s syntheses, demonstrates that synthetic
pathways requiring multiple reaction steps occur frequent-
ly in the patent literature. The 25 048 synthesis-containing
patents describe a total of 341 764 individual reaction
steps. While the most common are single-step syntheses,
52 462 syntheses (27.6%) have at least two reaction steps.
DISCUSSION
In addition to their direct value in intellectual property
licensing (15) and competitive business analysis (16),
patents can serve as a useful resource for a variety of
academic research. We examine the datasets used in
previous research and show that the data available in
SCRIPDB is sufﬁcient, quantitatively and qualitatively,
to provide value for future investigations. Additionally,
the information in patents is complementary to data avail-
able in the conventional academic literature (17), suggest-
ing additional insight may be derived from integration
with existing datasets. Speciﬁcally, we survey patent data
as a tool for the development of chemical image parsing,
biological text mining, reaction extraction, and bioisostere
discovery.
Patents as a source of chemical images
The problem of optical structure recognition is to auto-
matically extract molecular structure information from
images. A necessary resource in the training and evalu-
ation of such systems is a set of molecular images for
which the true molecular structure is already known.
Ideally, the images are representative of chemical images
as commonly used in practice.
Validation sets comprising 6185 images (18) and 454
images (19) were recently reported in the literature. By
comparison, SCRIPDB provides millions of CDX struc-
ture and TIFF image ﬁles. This comprises a validation set
several orders of magnitude larger than previously
reported, even after eliminating possibly-confounding
complex synthetic schemes. Furthermore, SCRIPDB
contains SVG images produced by OpenBabel in
addition to the original patent’s TIFF images. This redun-
dancy permits testing structure recognition algorithms for
robustness to the idiosyncrasies of alternative image gen-
eration tools.
Patents as biomedical literature
Statistical analysis of the biomedical literature requires
large quantities of freely accessible documents. Much of
the biological text mining research has therefore used
PubMed abstracts of journal articles while more recent
full-text analyses have focused on Open Access journals
(20). A large corpus of 162259 full-text journal articles in
HTML were used in the TREC Genomics track (21). The
Figure 5. Number of CDX data ﬁles that describe syntheses of various lengths.
Figure 4. Structures per patent in SCRIPDB. While 34,789 patents
contain ten or fewer structures, two-thirds of patents contain more
than ten and 1,296 patents contain more than a thousand structures.
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lection of comparable size.
Additionally, patents are interestingly complex. Patents
are inherently semistructured and are partially annotated
by their embedded chemical structures, gene sequences (7),
mathematical equations, and data tables. Patents also
contain citations to related papers (22) and patents,
permitting co-citation analysis. Patent relationships may
be derived and analyzed based on shared terms in patent
text, shared molecules, patent assignee (6) or ontological
categorization (http://www.uspto.gov/web/ofﬁces/opc/
documents/classescombined.pdf).
Patents as a reaction database
Libraries of chemical transforms are used for combinator-
ial library design (23), static synthetic feasibility (24), and
full retrosynthetic analysis (5). Although such libraries can
be constructed by hand (25), automated extraction is an
effective and labor-saving alternative (4,5,26,27). Such
systems determine molecular substructures that are
modiﬁed in the same manner across many different
syntheses. These modiﬁcations can then be treated as
putative reactions, predicting that if the same molecular
substructure is found in a new molecule, it can be changed
in the same way. Automated transform extraction there-
fore requires a large corpus of example syntheses within
which to ﬁnd consistent molecular changes.
In this capacity, SCRIPDB with its 341764 reactions
compares favorably to the 42 333 reactions in the
Methods in Organic Synthesis database recently used for
reaction extraction (5) or the 30530 CCR reactions used
to characterize functional group reactivity (28). While
smaller than commercial databases containing millions
of reactions, SCRIPDB has the virtue of being freely
accessible.
Patents as a bioisostere catalog
After ﬁnding an initial lead molecule, medicinal chemists
will typically create and test a large series of analogous
compounds, seeking to increase binding afﬁnity; improve
absorption, distribution, metabolism, excretion and
toxicity proﬁles; or avoid the intellectual property restric-
tions of competitors’ patents. One systematic approach for
exploring chemical space is to substitute bioisosteres,
which are molecular fragments that have similar shape
and chemical properties. For example, hydrogen and ﬂuor-
ine have similar van der Waals radii and the same valence.
Exchanging a hydrogen with a ﬂourine permits the medi-
cinal chemist to maintain the same molecular shape while
optimizing the molecule’s charge distribution.
There is strong interest both in techniques to determine
bioisosteres (29,30) and in idea-generation tools that
propose alternative molecules en masse by modifying a
lead molecule in silico using the same approach as a me-
dicinal chemist (31). Southall and Ajay (6) investigated
bioisosteric replacements in kinase patents by analyzing
116 550 compounds. The maximum common substructure
was computed for pairs of compounds and the remainder
of the molecules were identiﬁed as exchangeable chemical
replacements.
Southall and Ajay (6) were interested in the research
strategies of drug companies, so only compared com-
pounds found in patents assigned to different companies.
A similar analysis can be performed for the compound
series within a single patent (32). Each patent deﬁnes a
set of bioisosteric replacements that were determined to
be reasonable, interesting and synthetically feasible by a
medicinal chemist. Figure 4 demonstrates that SCRIPDB
contains sufﬁcient patents with large chemical series to
extract sensible chemical replacements.
CONCLUSION AND FUTURE WORK
The impetus of intellectual property protection creates a
deluge of patents that carries enormous quantities of
chemical and biological information. While patented mol-
ecules are accessible via chemical databases, the extraction
of component structures from a patent needlessly removes
information about chemical relationships. SCRIPDB is
designed to make such metadata broadly accessible. We
examined the information used in medical text mining,
chemical image parsing, reaction extraction and the devel-
opment of computational tools for lead optimization. We
demonstrated that the quantity and quality of SCRIPDB’s
data compares favorably with existing commercial and
free data sets. In many cases, it is complementary to
existing data.
In the future, we plan to reduce the manual interven-
tion necessary for the incorporation of new patents.
Automatic patent processing is critical for maintaining
the completeness of SCRIPDB, since new patents are
released weekly. Automated updating will also support
deposition of non-redundant molecules into PubChem
(1). In addition, we wish to pursue integration with
other value-adding databases, such as ChEMBL (33)
and CDIP (http://ophid.utoronto.ca/cdip), and provide
programmatic access to SCRIPDB via RESTful web
services.
Currently SCRIPDB incorporates patents only from the
United States, because the USPTO provides distinct struc-
ture ﬁles. However, valuable patent data is available from
other countries’ patent ofﬁces. Robust optical recognition
of chemical structures would permit future integration
with patent ofﬁces that provide molecules as images,
such as the European Patent Ofﬁce, the Japanese Patent
Ofﬁce, World Intellectual Property Organization, the UK
Intellectual Property Ofﬁce and the Canadian Intellectual
Property Ofﬁce.
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